Skin Disorders News

Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.

The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2024 focused on reducing stigma using social media.

Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology Congress.

Deucrictibant was well tolerated in daily 40 mg doses and showed no new safety signals among patients with hereditary angioedema, according to a poster presented at Bradykinin Symposium 2024 in Berlin.

Orismilast outperformed placebo in the treatment of moderate to severe atopic dermatitis in adults, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

New interim, long-term results showed that nemolizumab improved signs and symptoms of atopic dermatitis including sleep, itch and quality of life, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in Pediatric Allergy and Immunology.

Adolescents with hereditary angioedema experienced fewer attacks, improved quality of life and treatment satisfaction with lanadelumab, according to a study published in Annals of Allergy, Asthma & Immunology.

Zoryve cream 0.15% continues to show that it can provide clinical improvement to patients with atopic dermatitis, according to a press release.

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.